FR15C0079I2 - Expression optimisee de hpv 31 l1 dans la levure - Google Patents

Expression optimisee de hpv 31 l1 dans la levure

Info

Publication number: FR15C0079I2
Authority: FR; France
Prior art keywords: hpv31; yeast; polynucleotides; synthetic; protein
Prior art date: 2003-03-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR15C0079C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Organon Pharma UK Ltd

Merck Sharp and Dohme LLC

Original Assignee

Merck Sharp and Dohme Ltd

Merck Sharp and Dohme LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-24

Filing date

2015-12-04

Publication date

2016-11-25

2015-12-04 Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd

2016-08-01 Publication of FR15C0079I1 publication Critical patent/FR15C0079I1/fr

2016-11-25 Application granted granted Critical

2016-11-25 Publication of FR15C0079I2 publication Critical patent/FR15C0079I2/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Medical Informatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

FR15C0079C 2003-03-24 2015-12-04 Expression optimisee de hpv 31 l1 dans la levure Active FR15C0079I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US45717203P	2003-03-24	2003-03-24
PCT/US2004/008677 WO2004084831A2 (fr)	2003-03-24	2004-03-19	Expression optimisee de hpv 31 l1 dans la levure

Publications (2)

Publication Number	Publication Date
FR15C0079I1 FR15C0079I1 (fr)	2016-08-01
FR15C0079I2 true FR15C0079I2 (fr)	2016-11-25

Family

ID=33098208

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR15C0079C Active FR15C0079I2 (fr)	2003-03-24	2015-12-04	Expression optimisee de hpv 31 l1 dans la levure

Country Status (21)

Country	Link
US (2)	US7276243B2 (fr)
EP (1)	EP1608767B1 (fr)
JP (1)	JP4505452B2 (fr)
KR (1)	KR101080628B1 (fr)
CN (1)	CN100506999C (fr)
AT (1)	ATE546529T1 (fr)
AU (1)	AU2004224335B2 (fr)
BR (1)	BRPI0408639B8 (fr)
CA (1)	CA2519112C (fr)
EC (1)	ECSP056032A (fr)
ES (1)	ES2381964T3 (fr)
FR (1)	FR15C0079I2 (fr)
IL (1)	IL171067A (fr)
IS (1)	IS2859B (fr)
MX (1)	MXPA05010285A (fr)
NL (1)	NL300772I2 (fr)
NO (3)	NO341527B1 (fr)
NZ (1)	NZ542246A (fr)
RU (1)	RU2356943C2 (fr)
WO (1)	WO2004084831A2 (fr)
ZA (1)	ZA200507178B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7858098B2 (en) *	2002-12-20	2010-12-28	Glaxosmithkline Biologicals, S.A.	Vaccine
MY140664A (en)	2003-09-29	2010-01-15	Merck Sharp & Dohme	Optimized expression of hpv 45 l1 in yeast
MY139500A (en)	2003-11-12	2009-10-30	Merck Sharp & Dohme	Optimized expression of hpv 58 l1 in yeast
ES2343255T3 (es)	2004-03-24	2010-07-27	MERCK SHARP & DOHME CORP.	Expresion optimizada del vph 52 l1 en levadura.
JP4769247B2 (ja) *	2004-06-18	2011-09-07	インディアン・イムノロジカルズ・リミテッド	ヒトパピローマウイルス１６型に対するＳａｌｍｏｎｅｌｌａワクチン株に関するコドン最適化されたＨＰＶ１６Ｌ１
JP2006262846A (ja) *	2005-03-25	2006-10-05	Niigata Bio Research Park Kk	酵母による２−デオキシ−シロ−イノソースの合成および精製する方法並びに得られた２−デオキシ−シロ−イノソース
US20100203496A1 (en) *	2005-04-28	2010-08-12	Taddeo Frank J	Fluorescent Multiplex HPV PCR Assays
CN100392084C (zh) *	2006-03-13	2008-06-04	曾毅	含密码子优化型hpv16l1基因的重组腺病毒
KR100904844B1 (ko) *	2006-08-28	2009-06-25	성균관대학교산학협력단	인유두종 바이러스（ｈｐｖ）유전자를 포함하는자궁경부암의 치료 또는 예방용 ｄｎａ 백신
WO2008112125A1 (fr) *	2007-03-09	2008-09-18	Merck & Co., Inc.	Compositions de vaccin contre le papillomavirus
CN101113417B (zh) *	2007-06-22	2011-04-27	山东大学	Hpv基因酵母体外翻译系统的建立
MY182347A (en) *	2007-11-23	2021-01-20	Shanghai Zerun Biotechnology Co Ltd	Genes encoding major capsid protein l1 of human papilloma virus and use of the same
US20110201086A1 (en)	2010-02-12	2011-08-18	Otsuka Pharmaceutical Co., Ltd.	Method for producing recombinant virus
EP2576840B1 (fr)	2010-05-25	2018-10-17	QIAGEN Gaithersburg, Inc.	Analyse de capture hybride à résultats rapides et sondes associées tronquées de manière stratégique
WO2012177970A1 (fr)	2011-06-24	2012-12-27	Merck Sharp & Dohme Corp.	Formulation de vaccin contre le papillomavirus comprenant un adjuvant à l'aluminium, et procédé de production correspondant
CN109321592A (zh) *	2012-01-21	2019-02-12	北京安百胜生物科技有限公司	用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN103361377B (zh) *	2012-03-28	2017-12-05	北京安百胜生物科技有限公司	用汉逊酵母表达系统产生hpv6 l1蛋白的方法
CN108624614A (zh) *	2012-03-28	2018-10-09	北京安百胜生物科技有限公司	用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN104164374B (zh) *	2013-05-17	2019-10-22	北京安百胜生物科技有限公司	用汉逊酵母表达系统产生hpv31 l1蛋白的方法
CN104164373B (zh) *	2013-05-17	2019-04-02	北京安百胜生物科技有限公司	用汉逊酵母表达系统产生hpv68l1蛋白的方法
CN112280792B (zh) *	2013-09-29	2022-06-24	上海泽润生物科技有限公司	人乳头瘤病毒基因，及载体，菌株，表达方法
EP3057612B1 (fr)	2013-10-16	2020-05-06	Merck Sharp & Dohme Corp.	Procédé d'obtention de formulations de vaccin séchées thermostables
RU2546243C1 (ru) *	2014-02-13	2015-04-10	Закрытое акционерное общество научно-производственная компания "Комбиотех"	Рекомбинантная вакцина для профилактики папилломавирусной инфекции человека и способ ее получения
WO2016057954A2 (fr) *	2014-10-10	2016-04-14	Board Of Regents Of The University Of Texas System	Terminateurs exogènes pour contrôler l'expression génique fongique
EA201790944A1 (ru) *	2014-12-26	2017-11-30	Айджин, Инк.	Способ получения вирусоподобных частиц папилломавируса человека
CN117187263A (zh) *	2015-03-30	2023-12-08	上海泽润生物科技有限公司	重组人乳头瘤病毒33亚型蛋白表达
CN106701797B (zh) *	2015-08-12	2021-06-15	北京康乐卫士生物技术股份有限公司	31型重组人乳头瘤病毒病毒样颗粒及其制备方法
WO2017092710A1 (fr)	2015-12-04	2017-06-08	厦门大学	Mutant de la protéine l1 du virus du papillome humain de type 58
CN114127096B (zh) *	2019-07-19	2024-04-05	神州细胞工程有限公司	嵌合的人乳头瘤病毒31型l1蛋白
US11638754B2 (en)	2020-02-14	2023-05-02	Merck Sharp & Dohme Llc	HPV vaccine
CN113073105B (zh) *	2021-03-23	2023-06-13	重庆博唯佰泰生物制药有限公司	一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
US20230048144A1 (en)	2021-08-06	2023-02-16	Merck Sharp & Dohme Llc	Hpv vaccine
MX2024002144A (es)	2021-08-19	2024-04-23	Merck Sharp & Dohme Llc	Nueva nanoparticula lipidica termostable y metodos de uso de la misma.
CN118105476A (zh) *	2023-03-07	2024-05-31	北京康乐卫士生物技术股份有限公司	人乳头瘤病毒疫苗及其应用
TW202513091A (zh)	2023-06-09	2025-04-01	美商默沙東有限責任公司	用於人類乳突病毒疫苗之奈米乳液佐劑組合物
US20250281594A1 (en) *	2024-03-11	2025-09-11	Sk Bioscience Co., Ltd.	Truncated recombinant l1 protein of human papillomavirus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR004464A1 (es) *	1994-11-14	1998-12-16	Merck Sharp & Dohme	Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) *	1995-03-22	2005-11-20	Merck & Co Inc	Dna encoding human papillomavirus type 18
IL117591A0 (en)	1995-03-30	1996-07-23	Merck & Co Inc	Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5821087A (en) *	1995-03-30	1998-10-13	Merck & Co., Inc.	Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
JP2001512308A (ja)	1997-02-07	2001-08-21	メルクエンドカンパニーインコーポレーテッド	合成ｈｉｖｇａｇ遺伝子
EP1002091B1 (fr)	1997-07-09	2012-02-29	Coridon Pty Limited	Sequence d'acides nucleiques et procede pour exprimer, de maniere selective, une proteine dans une cellule ou un tissu cible
GB9717953D0 (en) *	1997-08-22	1997-10-29	Smithkline Beecham Biolog	Vaccine
FR2768748B1 (fr) *	1997-09-24	2001-06-08	Rhone Poulenc Agrochimie	Recodage de sequences d'adn permettant leur expression dans les levures et levures transformees obtenues
US6991795B1 (en) *	1998-08-14	2006-01-31	Merck & Co., Inc.	Protein delivery system using human papillomavirus virus-like particles
ATE344052T1 (de) *	1998-08-14	2006-11-15	Merck & Co Inc	Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
WO2001014416A2 (fr) *	1999-08-25	2001-03-01	Merck & Co., Inc.	Genes synthetiques humains du virus de papillome
US6436402B1 (en) *	1999-10-15	2002-08-20	Merck & Co., Inc.	Process for making human papillomavirus virus-like particles with improved properties
PT1301614E (pt)	2000-07-21	2007-02-28	Group Limited Glaxo	Sequências de codão optimizado do vírus do papiloma
KR100603747B1 (ko)	2000-07-26	2006-07-24	가부시키가이샤 신꼬간꾜우솔루션	수소·산소 공급 시스템
WO2003068163A2 (fr) *	2002-02-14	2003-08-21	Novavax, Inc.	Optimisation de sequences de genes de pseudo-particules virales chimeriques pour l'expression de cellules d'insectes
GB0206360D0 (en) *	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens

2004
- 2004-03-19 CA CA2519112A patent/CA2519112C/fr not_active Expired - Lifetime
- 2004-03-19 US US10/551,057 patent/US7276243B2/en not_active Expired - Lifetime
- 2004-03-19 JP JP2006507439A patent/JP4505452B2/ja not_active Expired - Lifetime
- 2004-03-19 AU AU2004224335A patent/AU2004224335B2/en active Active
- 2004-03-19 CN CNB2004800077258A patent/CN100506999C/zh not_active Expired - Lifetime
- 2004-03-19 RU RU2005132603/13A patent/RU2356943C2/ru active
- 2004-03-19 AT AT04757990T patent/ATE546529T1/de active
- 2004-03-19 MX MXPA05010285A patent/MXPA05010285A/es active IP Right Grant
- 2004-03-19 KR KR1020057017936A patent/KR101080628B1/ko not_active Expired - Lifetime
- 2004-03-19 WO PCT/US2004/008677 patent/WO2004084831A2/fr not_active Ceased
- 2004-03-19 ES ES04757990T patent/ES2381964T3/es not_active Expired - Lifetime
- 2004-03-19 EP EP04757990A patent/EP1608767B1/fr not_active Expired - Lifetime
- 2004-03-19 BR BRPI0408639A patent/BRPI0408639B8/pt not_active IP Right Cessation
- 2004-03-19 NZ NZ542246A patent/NZ542246A/en not_active IP Right Cessation
2005
- 2005-09-07 ZA ZA200507178A patent/ZA200507178B/xx unknown
- 2005-09-12 IS IS8019A patent/IS2859B/is unknown
- 2005-09-20 EC EC2005006032A patent/ECSP056032A/es unknown
- 2005-09-22 IL IL171067A patent/IL171067A/en active IP Right Grant
- 2005-10-21 NO NO20054889A patent/NO341527B1/no active Protection Beyond IP Right Term
2007
- 2007-07-19 US US11/879,905 patent/US7482428B2/en not_active Expired - Lifetime
2015
- 2015-11-30 NL NL300772C patent/NL300772I2/nl unknown
- 2015-12-04 FR FR15C0079C patent/FR15C0079I2/fr active Active
2018
- 2018-03-27 NO NO2018010C patent/NO2018010I1/no unknown
2022
- 2022-11-30 NO NO2022053C patent/NO2022053I1/no unknown

Also Published As

Publication number	Publication date
AU2004224335B2 (en)	2010-01-28
EP1608767A4 (fr)	2006-08-30
CA2519112A1 (fr)	2004-10-07
NL300772I1 (fr)	2015-12-29
ES2381964T3 (es)	2012-06-04
ATE546529T1 (de)	2012-03-15
EP1608767A2 (fr)	2005-12-28
NO341527B1 (no)	2017-12-04
RU2356943C2 (ru)	2009-05-27
WO2004084831A2 (fr)	2004-10-07
WO2004084831A3 (fr)	2004-11-11
CN100506999C (zh)	2009-07-01
BRPI0408639B8 (pt)	2021-05-25
IS2859B (is)	2013-12-15
RU2005132603A (ru)	2006-04-27
CA2519112C (fr)	2012-09-11
IS8019A (is)	2005-09-12
US20060177817A1 (en)	2006-08-10
BRPI0408639B1 (pt)	2020-08-18
JP4505452B2 (ja)	2010-07-21
NZ542246A (en)	2007-12-21
ZA200507178B (en)	2006-08-30
NO20054889L (no)	2005-12-19
JP2006523099A (ja)	2006-10-12
US7276243B2 (en)	2007-10-02
AU2004224335A1 (en)	2004-10-07
NO2022053I1 (no)	2022-11-30
US7482428B2 (en)	2009-01-27
KR20050119141A (ko)	2005-12-20
HK1090953A1 (zh)	2007-01-05
IL171067A (en)	2011-11-30
ECSP056032A (es)	2006-01-27
US20080166371A1 (en)	2008-07-10
KR101080628B1 (ko)	2011-11-08
CN1761759A (zh)	2006-04-19
NL300772I2 (fr)	2015-12-29
MXPA05010285A (es)	2005-11-17
FR15C0079I1 (fr)	2016-08-01
NO2018010I1 (no)	2018-03-27
EP1608767B1 (fr)	2012-02-22
NO20054889D0 (no)	2005-10-21
BRPI0408639A (pt)	2006-03-28

Publication	Publication Date	Title
NO2018010I1 (no)	2018-03-27	HPV 31 L1 protein
EP1687329B8 (fr)	2010-03-17	Expression optimisee de hpv 58 l1 dans de la levure
MY140664A (en)	2010-01-15	Optimized expression of hpv 45 l1 in yeast
MY148656A (en)	2013-05-15	Optimized expression of hpv 52 l1 in yeast.
AP1872A (en)	2008-08-04	Virus-like particles of human papillomavirus.
EP1246644A4 (fr)	2005-05-11	Reponse immunitaire cellulaire au papillomavirus humain induite par utilisation de compositions peptidiques et d'acide nucleique
WO2005020889A3 (fr)	2005-12-29	Particules pseudovirales de la grippe fonctionnelles (vlp)
WO1999061052A3 (fr)	2000-02-03	Immunisation par voie orale au moyen de particules de type viral du papillomavirus
TW200607858A (en)	2006-03-01	Optimized expression of HPV 31 L1 in yeast
EP1427443A4 (fr)	2006-03-08	Vaccin mettant en oeuvre des proteines e du virus du papillome administrees par vecteur viral
MY138895A (en)	2009-08-28	Optimized expression of hpv 31 l1 in yeast
DE602005022458D1 (de)	2010-09-02	Impfstoff gegen humanes papillomavirus zur oralen verabreichung
AR045249A1 (es)	2005-10-19	Expresion optimizada de hpv 31 l1 en levadura
WO2003090664A3 (fr)	2004-01-29	Polypeptide hpv-16 e7 mute, preparations pharmaceutiques le contenant, et son procede de preparation